Consilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93906Research ArticleKlinicheskie i ekonomicheskie perspektivy primeneniya ekstramelkodispersnykh aerozol'nykh ingalyatorovArkhipovV. V-MatveevN. V-151120131511222728122021Copyright © 2013, Consilium Medicum2013бронхиальная астмадозированные аэрозольные ингаляторы[Bisgaard H, O'Callaghan C, Smaldone G.C. Drug Delivery to the Lung. RC Press, 2001.][Usmani O.S, Biddiscombe M.F, Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005; 172 (12): 1497–504.][Atkins P.J. Dry Powder Inhalers: An Overview. Respir Care 2005; 50 (10): 1304–12.][Granlund K.M, Asking L, Lindblad T et al. An in - vitro comparison of budesonide/formoterol and fluticasone/salmeterol in dry powder inhalers. Eur Respir J 2000; 16 (Suppl. 31): 455s.][Yang T.T, Li S, Wyka B, Kenyon D. Drug delivery performance of the mometasone furoate dry powder inhaler. J Aerosol Med 2001; 14 (4): 487–94.][O’Callaghan C, Wright P, Bisgaard H. The metered - dose inhaler. Drug delivery to the lung. New York: Marcel Dekker, 2002: 337–70.][Mc Callister J.W, Moore W.C. Hydrofluoroalkane preparations of fluticasone propionate. Expert Rev Respir Med 2008; 2 (4): 433–42.][Escribano A, Tutuncu A, Löhr I et al. Clinical comparability between the CFC and HFA budesonide pressurized metered - dose inhalers in paediatric patients with asthma: a randomised controlled trial. Curr Med Res Opin 2006; 22: 1085–92.][Busse W.W, Brazinsky S, Jacobson K et al. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol 1999; 104: 1215–22.][Dolovich M. New delivery systems and propellants. Can Respir J 1999; 6 (3): 290–5.][Leach C.L, Davidson P.J, Boudreau R.J. Improved airway targeting with the CFC-free HFA-beclomethasone metered - dose inhaler compared with CFC-beclomethasone. Eur Respir J 1998; 12 (6): 1346–53.][Ganderton D, Lewis D, Davies R et al. Modulite: a means of designing the aerosols generated by pressurized metered dose inhalers. Respir Med 2002; 96 (Suppl. D): S3–8.][De Backer W, Devolder A, Poli G et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010; 23 (3): 137–48.][Cripps A, Riebe M, Schulze M, Woodhouse R. Pharmaceutical transition to non-CFC pressurized metered dose inhalers. Respir Med 2000; 94 (Suppl. B): S3–9.][Johnson M. Fluticasone Propionate: Pharmacokinetic and Pharmacodynamic Implications of Different Aerosol Delivery Systems. RDD VI 1998; 1: p. 61–70.][Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc - labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.][Thorsson L, Edsbäcker S, Conradson T.B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered - dose inhaler P-MDI. Eur Respir J 1994; 7 (10): 1839–44.][Mitchell J.P, Nagel M.W, Archer A.D. Size analysis of a pressurized metered dose inhaler - delivered suspension formulation by the API Aerosizer time - of - flight aerodynamic particle size analyzer. J Aerosol Med 1999; 12 (4): 255–64.][Hochrainer D, Hölz H, Kreher C et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers. J Aerosol Med 2005; 18 (3): 273–82.][Cerasoli F.Jr. Developing the ideal inhaled corticosteroid. Chest 2006; 130 (Suppl. 1): 54S–64S.][Nave R, Mc Cracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy 2008; 1: 11–8.][Newman S.P, Brown J, Steed K.P et al. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered - dose inhalers with and without spacer devices. Chest 1998; 113 (4): 957–63.][Richards J, Hirst P, Pitcairn G et al. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14 (2): 197–208.][Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc - labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.][Rau J.L. The Inhalation of Drugs: Advantages and Problems. Respir Care 2005; 50: 367–82.][Newman S.P. How Well Do In Vitro Particle Size Measurements Predict Drug Delivery In Vivo? J Aerosol Med 1998; 11 (s1): S-97–S-104.][Kelly H.W. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009; 43 (3): 519–27.][Usmani O.S. Treating the small airways. Respiration 2012; 84 (6): 441–53.][Weibel E.R. Design of airways and blood vessels considered as branching trees. The Lung: Sci Foundations 1991; 1: p. 711–20 (Eds - in - Chief, Crystal RG and West JB).][Stein S.W. Estimating the number of droplets and drug particles emitted from MDIs. AAPS Pharm Sci Tech 2008; 9 (1): 112–5.][Steckel H, Wehle S. A novel formulation technique for metered dose inhaler (MDI) suspensions. Int J Pharm 2004; 284 (1–2): 75–82.][Newmana S, Salmona A, Naveb R, Drollmannb A. High lung deposition of 99mTc - labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100: 375–84.][Thorsson L, Kenyon C, Newman S.P, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharmaceut 1998; 168: 119–27.][Cohen J, Douma W.R, ten Hacken N.H et al. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J 2008; 31 (6): 1213–20.][Hoshino M. Comparison of Effectiveness in Ciclesonide and Fluticasone Propionate on Small Airway Function in Mild Asthma. Allergol Int 2010; 59: 59–66.][Pedersen S. First European ADMIT Conference on Inhalation Devices in Asthma and COPD 2008.][Leach C.L, Davidson P.J, Hasselquist B.E, Boudreau R.J. Influence of particle size and patient dosing technique on lung deposition of HFA-beclomethasone from a metered dose inhaler. J Aerosol Med 2005; 18: 379–85.][Leach C.L, Davidson P.J, Hasselquist E, Boudreau R.J. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone. Chest 2002; 122: 510–6.][Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997; 91 (Suppl. A): 22–8.][Brutsche M.H, Brutsche I.C, Munawar M et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 2000; 356: 556–61.][Lipworth B.J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50 (2): 105–10.][Seale J.P, Harrison L.I. Effect of changing the fine particle mass of inhaled beclomethasone dipropionate on intrapulmonary deposition and pharmacokinetics. Respir Med 1998; 92 (Suppl. A): 9–15.][Holz O, Zühlke I, Einhaus M et al. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulm Pharmacol Ther 2004; 17 (4): 233–8.][Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc - labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006; 100 (3): 375–84.][Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005; 18 (6): 390–6.][Nave R, Mc Cracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy 2008; 1: 11–8.][Nave R, Mc Cracken N. Metabolism of ciclesonide in the upper and lower airways: review of available data. J Asthma Allergy. 2008; 1: 11–8.][Johnson M, Dalby R, Byron P et al. Fluticasone propionate: pharmacokinetic and pharmacodynamic implications of different aerosol delivery systems. Buffalo Grove, IL: Interpharm Press. Respir Drug Delivery VI. 1998; p. 61–70.][Pitcairn G, Reader S, Pavia D, Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 2005; 18 (3): 264–72.][Доклад рабочей группы GINA (Global Initiative for Asthma), пересмотр 2012 г. // www.ginasthma.org][ATC/DDD Index 2013 WHO Collaborating Centre for Drug Statistics Methodology; http://www.whocc.no/atc_ddd_index/]